阿坎托利性疾病:关于病理生理学,诊断和管理的最新情况
Maggie H Zhou1, Thomas P Stirrat2, John R Edminister3
1Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
Journal of the American Academy of Dermatology
|February 23, 2026
概括
像达里尔病和海利-海利病这样的阿坎托利性皮肤疾病会损害皮肤细胞的粘附性. 本综述涵盖了除类固醇之外的诊断和新兴治疗方法,包括生物药物和这些罕见疾病的新疗法.
科学领域:
- 皮肤病学 皮肤病学
- 细胞生物学 细胞生物学
- 遗传学 遗传学 是一个
背景情况:
- 乙醇性皮肤疾病破坏了角质细胞中的细胞间粘附.
- 遗传形式包括达里尔病 (DD) 和海利-海利病 (HHD);格罗弗病 (GD) 的发病原因尚不清楚.
- 这些罕见的疾病往往带来诊断挑战,缺乏标准化的治疗指南.
研究的目的:
- 为医生提供对acantholytic疾病的诊断标准.
- 对这些疾病的现有和新兴治疗策略进行审查.
- 根据最近的证据提供专家治疗建议.
主要方法:
- 关于阿坎托利性皮肤疾病的文献综述.
- 分析当前的治疗方式,包括局部类固醇,视网,生物药物和小分子抑制剂.
- 探索新的治疗点和药物.
主要成果:
- 已建立的治疗方法,如局部类固醇和视网类药物,具有可变的疗效.
- 新兴的疗法包括生物药物 (例如,dupilumab,TNF-α抑制剂),JAK抑制剂,以及耐火病例的apremilast.
- 低剂量纳尔特雷克松显示出作为单一疗法或辅助治疗的潜力.
- 准IL-17/23,IL-4/13轴,MAPK/ERK通路和SERCA激活剂是新的策略.
结论:
- 由于诊断的挑战,对acantholytic疾病的准确诊断至关重要.
- 选择治疗方法时应考虑疾病的严重程度和新出现的证据.
- 新的治疗途径为治疗不耐药和严重病例提供了希望.
相关概念视频
01:29Inflammatory Bowel Disease IV: Pharmacological Management
842
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
842
01:17Chronic Bowel Disorders: Introduction
841
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
841
01:29Drugs for Treatment of Ulcerative Colitis in IBD
577
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577
01:17Drugs for Treatment of Diarrhea-Predominant IBS
783
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
783
01:26Atherosclerosis III: Management
482
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
482
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
1.3K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.3K